The average one-year price target for Instil Bio (NasdaqCM:TIL) has been revised to $97.66 / share. This is an increase of 41.50% from the prior estimate of $69.02 dated September 27, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $27.27 to a high of $189.00 / share. The average price target represents an increase of 421.44% from the latest reported closing price of $18.73 / share.
What is the Fund Sentiment?
There are 75 funds or institutions reporting positions in Instil Bio. This is an decrease of 6 owner(s) or 7.41% in the last quarter. Average portfolio weight of all funds dedicated to TIL is 0.71%, an increase of 3.17%. Total shares owned by institutions decreased in the last three months by 11.19% to 4,740K shares.
What are Other Shareholders Doing?
Curative Ventures V holds 1,899K shares representing 28.13% ownership of the company. No change in the last quarter.
BML Capital Management holds 535K shares representing 7.92% ownership of the company. In its prior filing, the firm reported owning 417K shares , representing an increase of 22.09%. The firm increased its portfolio allocation in TIL by 43.98% over the last quarter.
CPMG holds 411K shares representing 6.09% ownership of the company. No change in the last quarter.
Vivo Capital holds 293K shares representing 4.34% ownership of the company. In its prior filing, the firm reported owning 585K shares , representing a decrease of 100.00%. The firm decreased its portfolio allocation in TIL by 53.64% over the last quarter.
Siren, L.L.C. holds 204K shares representing 3.02% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
